GLP-1 receptor agonists × body weight & composition

TrialJAMA2015

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.

Melanie J Davies et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 1,361 people · 2015

Randomised comparison

Lowered body weight & composition

−4.00percentage points−5.10 to −2.90

As reported

difference −4.00 %, 95% CI −5.10 to −2.90

Randomised comparison

Raised body weight & composition

+32.9percentage points+24.6 to +41.2

As reported

difference 32.9 %, 95% CI 24.6–41.2

Randomised comparison

Raised body weight & composition

+18.5percentage points+12.7 to +24.4

As reported

difference 18.5 %, 95% CI 12.7–24.4

Three numbers in the abstract

the abstract, start to end

for liraglutide [3.0 mg] vs placebo, -4.00% [95% CI, -5.10% to -2.90%];

for liraglutide [3.0 mg] vs placebo, 32.9% [95% CI, 24.6% to 41.2%]; for

for liraglutide [3.0 mg] vs placebo, 18.5% [95% CI, 12.7% to 24.4%],

← favours treatmentfavours comparator →
could be chance
Body weight & composition
−4.00−5.10 to −2.90
Body weight & composition
32.924.6–41.2
Body weight & composition
18.512.7–24.4
GLP-1 receptor agonistsBody weight & composition

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely
0.900.90 without it
← favours comparatorfavours treatment →
this papermore certainless certain
1 / 5

495 papers cite itlatest 60 shown

2015
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 26284720